Our Company
Addressing unmet needs for clinical
validation of medicinal cannabis.
Zelda Therapeutics is an Australian
ASX listed company (ASX: ZLD).
Research Focus
Zelda Therapeutics has been formed to bring together some of the world’s leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.
Latest News
- Appendix 4C - quarterly
- June 2021 Quarterly Activities Report
- US Observational Clinical Pain Trial Receives IRB Approval
- Pershing trading restrictions for cannabis companies lifted
- Cantor Fitzgerald - Investor Presentation
- Australian medicinal cannabis revenue tipped to reach $200 million in 2021 – The West Australian
- 18 Minutes with Zelira Therapeutics – 180 Markets
- 18 Minutes with Zelira Therapeutics – 180 Markets
- Cantor Fitzgerald Hosts Fireside Chat with Zelira Therapeutics
- Cantor Fitzgerald Hosts Fireside Chat with Zelira Therapeutics
- Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme
- Medicinal cannabis trial could help retired AFL players manage chronic pain
- Medicinal cannabis trial could help retired AFL players manage chronic pain
- Sequoia Initiation Research Report, 19 August 2020
- Sequoia Initiation Strong Buy, 19 August 2020
- Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
- Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11
- Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
- Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints
- Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial
OUR PARTNERS
 |
 |
 |
 |
 |
 |
 |
 |
 |